Prof of Molecular Immunology at University of Birmingham, UK, and Director of the Cancer Immunology and Immunotherapy Centre at UoB. Father of two manic girls.
Want to get up to speed with immune checkpoint blockade therapy for cancer ?
Register now for this online 13-hour CPD course ‘Understanding immune checkpoint blockade therapy: a pillar of modern cancer treatment’, from the University of Birmingham, UK, starting on Jan 24th, 2024.
@forum_gd @ErinJAdams Great talks ! A q. for Erin...What is the phenotype of the CD1-reactive Vδ1 cells (eg Tnaive vs Teffector) ?? Given huge diversity in the Vδ1 TCR repertoire and in the CD1 binding modes, do some reflect the ‘universe of possibilities’ – rather than Teffector specificities ??
Exciting day for us launching our new #DiversityandInclusion framework! I’m so proud of the team and our membership for all we’ve done to date, but there’s always more we can do. Have a read to see how we are going to take this forward with our members and wonderful community 👇
26 years ago, a gunman entered
Dunblane Primary School in Scotland,
killing 16 kids and a teacher. The UK
govt responded by enacting tight gun
control legislation. In the 9400+ days
since, there have been a total of O
school shootings in the UK. #Uvalde
Great to get McMurray et al out in Cell Reports, a page turner about transcriptional control of adaptive gd T cells. Thx to all co-authors and congrats to the talented @JackMcMurray. Strong similarities to ab T cells bring things back to ligand recognition as key gd USP.
@forum_gd Super-impressive paper (Singh et al) in Nature on a new ‘immunoantibiotic’ approach to tackle drug resistant microbes, which enlists the help of Vγ9Vδ2 T cells. Here is our News and Views, co-authored with @Youcef_Mehellou https://t.co/lPwLD5oZuP
An ‘immunoantibiotic’ drug launches a two-pronged attack on antibiotic-resistant microbes. Learn more this terrific N&V by @Youcef_Mehellou & @profbenw
https://t.co/MBHVO42uQZ
Super-impressive study by Singh et al in Nature on an ‘immunoantibiotic’ approach to tackle drug resistant microbes, enlisting help from γδ T cells. Check out our News and Views, co-authored with @Youcef_Mehellou. https://t.co/lPwLD5oZuP @NatureNV@ImmunologyUoB@IMIBirmingham
Massive congratulations to David Bending for scooping an MRC Career Development Fellowship ! Great to see a young scientist get career-changing support. So happy for him and @BendingLab.
@CRUKResearch
Extremely informative visit to the CRUK Birmingham Centre from CRUK’s CDD team and the CRUK-Astra Zeneca Antibody Alliance Laboratory yesterday. Many thanks to Nigel Blackburn, Rob Williams and Julie Little for helping us take our research from lab to patient !
Check out our new paper in Immunity 👉🏻 “Butyrophilin-like 3 Directly Binds a Human Vγ4+ T Cell Receptor Using a Modality Distinct from Clonally-Restricted Antigen”
https://t.co/bfYIdg0j0N
•
#gdTcells @forum_gd @unibirm_MDS @CIIC_UoB@ImmunologyUoB@ImmunityCP#immunology#Tcells
@StridLab Thanks Jessica, yes it will be fun to see how far this superantigen-like paradigm takes us all. It was great to work with the Haydays on this !